Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Universitätsklinikum Hamburg-Eppendorf |
---|---|
Information provided by: | Universitätsklinikum Hamburg-Eppendorf |
ClinicalTrials.gov Identifier: | NCT00778752 |
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (University Medical Center Hamburg-Eppendorf/ University Medical Center Heidelberg).
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: Revlimid (Lenalidomide) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Dose-Finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation |
Estimated Enrollment: | 25 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | November 2013 |
Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.
|
Drug: Revlimid (Lenalidomide)
3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall. If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall. If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Laboratory test results within these ranges:
Exclusion Criteria:
Contact: Nicolaus Kroeger, Prof. Dr. | +49-40-42803-5864 | nkroeger@uke.uni-hamburg.de |
Contact: Marion Heinzelmann, R.N. | +49-40-42803-4188 | mheinzel@uke.uni-hamburg.de |
Germany | |
Universitätsklinikum Heidelberg | Recruiting |
Heidelberg, Germany, 69120 | |
Contact: Stefan Schoenland, Dr. stefan.schoenland@med.uni-heidelberg.de | |
Universitätsklinikum Hamburg-Eppendorf | Recruiting |
Hamburg, Germany, 20246 | |
Contact: Nicolaus Kroeger, Prof. Dr. +49-40-42803-5864 nkroeger@uke.uni-hamburg.de |
Principal Investigator: | Nicolaus Kroeger, Prof. Dr. | University Medical Center Hamburg-Eppendorf, Germany |
Responsible Party: | Universitätsklinikum Hamburg-Eppendorf ( Prof. N. Kroeger ) |
Study ID Numbers: | Revlimid as maintenance in MM |
Study First Received: | October 22, 2008 |
Last Updated: | April 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00778752 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Germany: Paul-Ehrlich-Institut |
Multiple Myeloma Stem Cell Transplantation Revlimid Lenalidomide |
Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases Lenalidomide Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Signs and Symptoms Hemorrhagic Disorders Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents Blood Protein Disorders Hematologic Diseases Lenalidomide Vascular Diseases Paraproteinemias |
Hemostatic Disorders Pharmacologic Actions Multiple Myeloma Neoplasms Hemorrhagic Disorders Therapeutic Uses Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |